| Literature DB >> 29214768 |
Gianluca Caridi1, Abdelbasset Maout2, Reha Artan3, Monica Campagnoli4, Francesca Lugani1, Mohamed El Amine Abada2, Ersin Sayar3, Monica Galliano4, Lorenzo Minchiotti5.
Abstract
Entities:
Mesh:
Substances:
Year: 2018 PMID: 29214768 PMCID: PMC5736683 DOI: 10.3343/alm.2018.38.2.185
Source DB: PubMed Journal: Ann Lab Med ISSN: 2234-3806 Impact factor: 3.464
Laboratory data of the three analbuminemic patients
| Analyte | Algerian patient | Reference range* | Turkish patient 1 | Turkish patient 2 | Reference range† |
|---|---|---|---|---|---|
| Albumin (g/L)‡ | ND | NR | 39.7–49.4 | ||
| Albumin (g/L)¶ | 32.0–50.0 | ND | ND | NR | |
| Total protein (g/L) | 60.0–75.0 | 66.0–87.0 | |||
| Albumin (g/L)** | 32.0–50.0 | 36.1–45.9 | |||
| Alpha1-globulins (g/L)** | 4.0 | 1.0–4.0 | 1.7–4.4 | ||
| Alpha2-globulins (g/L)** | 5.0–11.0 | 3.2–9.1 | |||
| Beta1-globulins (g/L)** | ND | NR | 7.8 | 3.5–8.0 | |
| Beta2-globulins (g/L)** | ND | NR | 4.1 | 3.7 | 1.6–6.2 |
| Beta-globulins (g/L)** | 6.0–13.0 | NR | NR | NR | |
| Gamma-globulins (g/L)** | 7.0–15.0 | 13.0 | 14.8 | 6.3–16.4 | |
| IgG (g/L) | 6.5–13.5 | 13.9 | 7.0–16.0 | ||
| IgM (g/L) | 1.5 | 0.3–2.5 | 0.2–2.5 | ||
| IgA (g/L) | 2.7 | 1.0–4.0 | 2.4 | 2.4 | 0.02–2.5 |
| Alpha-1-antitrypsin (g/L) | 2.4 | 1.8–4.0 | 0.9–2.0 | ||
| Transferrin (g/L) | 2.0–3.6 | 3.5 | 3.5 | 2.0–3.6 | |
| Ferritin (µg/L) | 13.0–150.0 | 13.0–150.0 | |||
| Prealbumin (g/L) | ND | NR | 0.4 | 0.2–0.4 | |
| Haptoglobin (g/L) | 0.3–1.5 | ND | ND | NR | |
| Lipoprotein(a) (g/L) | ND | NR | 0.01–30.0 | ||
| Triglycerides (mmol/L) | 1.0 | 0.6–1.7 | 2.2 | 1.9 | 0.6–2.3 |
| Total cholesterol (mmol/L) | 4.1–5.2 | 4.7 | 3.9–5.2 | ||
| HDL-cholesterol (mmol/L) | 1.5 | 1.0–2.5 | 1.7 | 1.2 | 0.9–1.9 |
| LDL-cholesterol (mmol/L) | < 4.1 | 2.7 | 1.5–3.4 | ||
| Calcium (mmol/L) | 2.0–2.6 | 2.1 | ND | 2.1–2.5 | |
| Ionized calcium (mmol/L) | 1.2–1.3 | ND | ND | NR | |
| Phosphate (mg/L) | 30.0 | 25.0–48.0 | 38.9 | ND | 25.0–45.0 |
| Proteinuria (mg/24 hr) | Absent | < 300 | 66.0 | 110.0 | 40.0–150.0 |
| Micro-albuminuria (mg/24 hr) | Absent | < 30.0 | 0.7 | 0.01 | 0.0–30.0 |
Abnormal values are highlighted in bold.
*Measured in the Algerian laboratory; †Measured in the Turkish laboratory; ‡Modified bromocresol green-binding assay; ¶Immunonephelometric determination; **Measured by electophoretic analysis.
Abbreviations: ND, not detected; NR, not reported.
Fig. 1Heteroduplex, single strand conformational polymorphism, and DNA sequence analyses of the variant region of the ALB gene in the two affected families. (A) Heteroduplex analysis and single strand conformational polymorphism. The DNA encompassing this region of the ALB gene of four members of the Turkish family, two members of the Algerian family, and two controls was amplified with the PCR primers A19B and A20C [4], and the fragments were electrophoresed onto a non-denaturing polyacrylamide gel. Turkish family: lane 1, patient 2; lane 2, patient 1; lane 3, mother; lane 4, father. Algerian family: lane 5, patient, and lane 6, father. Lanes 7–8, controls. The same samples were denatured and cooled before loading. Turkish family: lane 1´, patient 2; lane 2´, patient 1; lane 3´, mother; lane 4´, father. Algerian family: lane 5´, patient and lane 6´, father. Lanes 7´–8´, controls. (B) Genomic DNA sequence electropherograms of the variant region of the ALB gene in the Algerian family. The arrow indicates the G>A transition at position c.1289+1, the first base of intron 10. The patient is homozygous for the mutation, while the father is heterozygous for the wild-type and mutated alleles, as evidenced by the presence of two superimposed peaks.